European Journal of Cancer, Supplement Q2 Unclaimed
European Journal of Cancer, Supplement is a journal indexed in SJR in Oncology and Cancer Research with an H index of 29. It is an CC BY-NC-ND Journal with a Single blind Peer Review review system, and It has a price of 2700 €. The scope of the journal is focused on cancer, translational oncology, clinical oncology, cancer epidemiology, cancer prevention. It has an SJR impact factor of 0,759 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,759.
Type: Journal
Type of Copyright: CC BY-NC-ND
Languages: English
Open Access Policy: Open Access
Type of publications:
Publication frecuency: -
2700 €
Inmediate OANPD
Embargoed OA- €
Non OAMetrics
0,759
SJR Impact factor29
H Index0
Total Docs (Last Year)14
Total Docs (3 years)0
Total Refs31
Total Cites (3 years)13
Citable Docs (3 years)0.33
Cites/Doc (2 years)0.0
Ref/DocOther journals with similar parameters
International Journal of Oncology Q2
BMC Cancer Q2
Cancer Epidemiology Q2
Frontiers in Oncology Q2
Journal of Geriatric Oncology Q2
Compare this journals
Aims and Scope
Best articles by citations
74 How do we choose new molecular targets for clinical exploitation?
View more16 A combined analysis of three European audits of primary breast cancer management
View more75 p53 signaling and novel mechanisms for targeted radiosensitizers
View more76 EGF-receptor inhibition and radiotherapy
View more36 Paclitaxel/Carboplatin(TC) vs Paclitaxel/Carboplatin sequentially followed by Topotecan (TC-Top) in first-line treatment of ovarian cancer Flgo stages IIB -IV interim results of a gynaecologic cancer intergroup phase III trial of the Ago ovarian c
View more25 Repopulation in human squamous cell carcinoma FaDu: possible impact of the impairment of recovery from sublethal damage repair
View more60 Concurrent targeted and chemotherapy treatments is the best way to go
View more77 The PI3K/AKT pathway: a target for new chemo-radiation approaches?
View more78 Modulators of apoptotic signalling
View more79 Molecular determinants of glioma biology
View more10 Cancer related anemia and its modification
View more37 Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer (AOC): long-term efficacy results
View more61 Concurrent targeted and chemotherapy treatments is the best way to go. CONTRA
View more38 Influence of amifostine on neuroprotection in 1st-line treatment of advanced ovarian cancer with carboplatin/taxane-based chemotherapy - a double-blind, placebo-controlled, randomized phase II-study from the AGO Ovarian Cancer Study Group
View more41 HER2-expression in advanced ovarian cancer: A prognostic and predictive marker? An study of the AGO ovarian study group
View more62 Who should receive adjuvant treatment?
View more39 Topotecan versus treosulfan in recurrent ovarian cancer after initial chemotherapy with platinum and paclitaxel. a prospective randomised phase III study of the AGO ovarian cancer study group
View more8 Proteomics in translational cancer research
View more63 Tailored adjuvant therapies
View more26 Single nucleotide polymorphisms in candidate genes correlate with clinical normal tissue radiosensitivity
View more13 The biology of paediatric cancer
View more17 Can danish breast cancer patients by early diagnosis achieve the same survival as observed in Sweden? A study in screened and non-screened Danish and Swedish populations
View more42 Phase I study for treatment of ovarian cancer patients with symptomatic ascites using the trifunctional bispecific antibody removab® (anti-CD3 X anti-EpCAM)
View more64 The prognostic and predictive role of HER-2 and topoisomerase II alpha in breast cancer (BC)
View more
Comments